<VariationArchive VariationID="992230" VariationName="NM_000169.3(GLA):c.559_560del (p.Met187fs)" VariationType="Deletion" Accession="VCV000992230" Version="4" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-07-15" DateCreated="2021-01-07" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="980206" VariationID="992230">
      <GeneList>
        <Gene Symbol="GLA" FullName="galactosidase alpha" GeneID="2717" HGNC_ID="HGNC:4296" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>Xq22.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101397803" stop="101407925" display_start="101397803" display_stop="101407925" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100652778" stop="100663000" display_start="100652778" display_stop="100663000" Strand="-" />
          </Location>
          <OMIM>300644</OMIM>
          <Haploinsufficiency last_evaluated="2021-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GLA">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-03-24" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GLA">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
        <Gene Symbol="RPL36A-HNRNPH2" FullName="RPL36A-HNRNPH2 readthrough" GeneID="100529097" HGNC_ID="HGNC:48349" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>Xq22.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101391011" stop="101414133" display_start="101391011" display_stop="101414133" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100645877" stop="100669127" display_start="100645877" display_stop="100669127" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000169.3(GLA):c.559_560del (p.Met187fs)</Name>
      <CanonicalSPDI>NC_000023.11:101400744:AT:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xq22.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="101400745" stop="101400746" display_start="101400745" display_stop="101400746" variantLength="2" positionVCF="101400744" referenceAlleleVCF="CAT" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="100655733" stop="100655734" display_start="100655733" display_stop="100655734" variantLength="2" positionVCF="100655732" referenceAlleleVCF="CAT" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>M187fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.100655733_100655734del" Assembly="GRCh37">
            <Expression>NC_000023.10:g.100655733_100655734del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.101400745_101400746del" Assembly="GRCh38">
            <Expression>NC_000023.11:g.101400745_101400746del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007119.1" sequenceAccession="NG_007119" sequenceVersion="1" change="g.12218_12219del">
            <Expression>NG_007119.1:g.12218_12219del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000169.3" sequenceAccession="NM_000169" sequenceVersion="3" change="c.559_560del" MANESelect="true">
            <Expression>NM_000169.3:c.559_560del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000160.1" sequenceAccession="NP_000160" sequenceVersion="1" change="p.Met187fs">
            <Expression>NP_000160.1:p.Met187fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_164783.1" sequenceAccession="NR_164783" sequenceVersion="1" change="n.581_582del">
            <Expression>NR_164783.1:n.581_582del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001199973.2" sequenceAccession="NM_001199973" sequenceVersion="2" change="c.300+5288_300+5289del">
            <Expression>NM_001199973.2:c.300+5288_300+5289del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001199974.2" sequenceAccession="NM_001199974" sequenceVersion="2" change="c.177+8923_177+8924del">
            <Expression>NM_001199974.2:c.177+8923_177+8924del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_672" sequenceAccession="LRG_672">
            <Expression>LRG_672:g.12218_12219del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_672t1" sequenceAccession="LRG_672t1">
            <Expression>LRG_672t1:c.559_560del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1928287177" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000169.3(GLA):c.559_560del (p.Met187fs) AND Fabry disease" Accession="RCV001280614" Version="4">
        <ClassifiedConditionList TraitSetID="3012">
          <ClassifiedCondition DB="MedGen" ID="C0002986">Fabry disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-04-03" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-04-03" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2021-01-07" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10666480</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12175777</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28728877</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29543226</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30644091</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31449323</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3012" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1790" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Fabry's disease</ElementValue>
                <XRef ID="Fabry+Disease/2690" DB="Genetic Alliance" />
                <XRef ID="16652001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ceramide trihexosidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Fabry disease</ElementValue>
                <XRef ID="MONDO:0010526" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Angiokeratoma, diffuse</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Anderson-Fabry disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary dystopic lipidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha-galactosidase A deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLA deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Angiokeratoma corporis diffusum</ElementValue>
                <XRef ID="HP:0001071" DB="Human Phenotype Ontology" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ceramide trihexosidase deficiency</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6400" />
                <XRef ID="6400" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism">Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.</Attribute>
                <XRef ID="GTR000500007" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Fabry disease is the most common of the lysosomal storage disorders and results from deficient activity of the enzyme alpha-galactosidase A (α-Gal A), leading to progressive lysosomal deposition of globotriaosylceramide and its derivatives in cells throughout the body. The classic form, occurring in males with less than 1% α-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, females may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, late-onset forms occur in males with greater than 1% α-Gal A activity. Clinical manifestations include cardiac disease, which usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy, arrhythmia, and proteinuria; renal failure, associated with ESRD but without the skin lesions or pain; or cerebrovascular disease presenting as stroke or transient ischemic attack.</Attribute>
                <XRef ID="NBK1292" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000556520" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591289" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528276" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507480" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520414" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551442" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512526" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520063" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514924" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000568367" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000596367" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558532" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552214" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505068" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528536" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522527" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528516" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528500" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528528" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325415" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000556501" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000246735" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520447" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000260631" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301469</ID>
                <ID Source="BookShelf">NBK1292</ID>
              </Citation>
              <Citation Type="general">
                <ID Source="pmc">3009617</ID>
              </Citation>
              <Citation Type="general" Abbrev="HFSA, 2010">
                <ID Source="PubMed">20610207</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2002">
                <ID Source="PubMed">12735292</ID>
              </Citation>
              <Citation Type="general" Abbrev="Eng et al., 2006">
                <ID Source="PubMed">16980809</ID>
              </Citation>
              <Citation Type="general" Abbrev="Salviati et al, 2010">
                <ID Source="pmc">2869001</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGentest, 2011">
                <ID Source="PubMed">21934708</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="AHA/ASA, 2014">
                <ID Source="PubMed">25355838</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23860966</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173338</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="AHA/ACC/HFSA, 2022">
                <ID Source="PubMed">35378257</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACC/AHA/HFSA, 2017">
                <ID Source="PubMed">28461259</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Fabry.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased a-galactosidase A, Fabry Disease, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Fabry-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Alpha-galactosidase A (alpha- gal A) Deficiency, 2022</CitationText>
              </Citation>
              <XRef ID="324" DB="Orphanet" />
              <XRef ID="C0002986" DB="MedGen" />
              <XRef ID="MONDO:0010526" DB="MONDO" />
              <XRef Type="MIM" ID="301500" DB="OMIM" />
              <XRef Type="primary" ID="HP:0001071" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2892528" SubmissionDate="2020-12-31" DateLastUpdated="2021-01-07" DateCreated="2021-01-07">
        <ClinVarSubmissionID localKey="NM_000169.2:c.559_560delAT|MedGen:C0002986" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001467833" DateUpdated="2021-01-07" DateCreated="2021-01-07" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-12-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">30644091</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28728877</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31449323</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29543226</ID>
          </Citation>
          <Comment>Variant summary: GLA c.559_560delAT (p.Met187ValfsX6) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 181428 control chromosomes. c.559_560delAT has been reported in the literature in individuals affected with classic manifestations of Fabry Disease and associated with elevated serum Lyso-Gb3 levels in males with a classic disease presentation (example, Nowak_2019, Nowak_2017, Barbey_2019, Maruyama_2019). At least one publication reports experimental evidence evaluating an impact on protein function in a carrier female. The most pronounced variant effect results in alpha-Gal A enzyme activity within the levels expected for a carrier female and can be extrapolated to &lt;10% of normal activity in classic male patients (Maruyama_2019). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000169.2:c.559_560delAT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Fabry disease</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0002986" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8831147</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="6150688" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="5902164|MedGen:C0002986" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003461841" DateUpdated="2024-02-20" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-04-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">28728877</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10666480</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12175777</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 992230). This premature translational stop signal has been observed in individual(s) with Fabry disease (PMID: 28728877). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Met187Valfs*6) in the GLA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GLA are known to be pathogenic (PMID: 10666480, 12175777).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.100655733_100655734del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0002986" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2892528" TraitType="Disease" MappingType="Name" MappingValue="Fabry disease" MappingRef="Preferred">
        <MedGen CUI="C0002986" Name="Fabry disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="6150688" TraitType="Disease" MappingType="XRef" MappingValue="C0002986" MappingRef="MedGen">
        <MedGen CUI="C0002986" Name="Fabry disease" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

